13 leading drugmakers' top 3 drugs by revenue in 2020

The best-selling drug in the world in 2020 was AbbVie's Humira, an immunology drug used to treat rheumatoid arthritis and other inflammatory diseases, according to a report published March 22 by S&P Global. 

In 2020, Humira generated $19.83 billion in revenue for a 3.5 percent increase over 2019. 

The three top drugs by 2020 revenue for 13 leading drugmakers:

AbbVie 

1. Humira — $19.83 billion 
2. Imbruvica — $5.31 billion 
3. Botox — $2.50 billion 

Merck 

1. Keytruda — $14.38 billion 
2. Gardasil/Gardasil 9 — $3.94 billion 
3. Januvia — $3.31 billion 

Bristol Myers Squibb 

1. Revlimid — $12.11 billion 
2. Eliquis — $9.17 billion 
3. Opdivo — $6.99 billion 

Pfizer 

1. Prevnar 13/Prevenar 13 — $5.85 billion 
2. Ibrance — $5.39 billion 
3. Eliquis — $4.95 billion 

Johnson & Johnson 

1. Stelara — $7.71 billion
2. Darzalex — $4.19 billion 
3. Imbruvica — $4.13 billion 

Gilead 

1. Biktarvy — $7.26 billion 
2. Genvoya — $3.34 billion 
3. Veklury — $2.81 billion 

Amgen 

1. Enbrel — $5 billion 
2. Prolia — $2.76 billion 
3. Neulasta — $2.29 billion 

Novartis 

1. Cosentyx — $4 billion 
2. Gilenya — $3 billion 
3. Entresto — $2.5 billion 

Eli Lilly

1. Trulicity — $5.07 billion 
2. Humalog — $2.63 billion 
3. Alimta — $2.33 billion 

Sanofi 

1. Dupixent — $4.04 billion 
2. Lantus  — $3.04 billion 
3. Influenza vaccine — $2.82 billion 

AstraZeneca 

1. Tagrisso — $4.33 billion 
2. Symbicort — $2.72 billion 
3. Imfinzi — $2.04  billion 

Novo Nordisk

1. Ozempic — $3.25 billion 
2. Victoza — $2.87 billion 
3. NovoRapid/NovoLog — $2.59 billion 

GlaxoSmithKline 

1. Triumeq — $2.96 billion 
2. Shingrix — $2.55 billion 
3. Seretide/Advair — $1.97 billion

More articles on pharmacy:
NIAID: AstraZeneca's COVID-19 vaccine data may be outdated
Pfizer to develop more mRNA vaccines
Regeneron says its COVID-19 antibody cocktail reduces hospitalization, death risk by 70%